2 Greenwich Office Park
Suite 210
Greenwich, CT 06831
203 863-0003
77 Lafayette Place
Suite 302
Greenwich, CT 06830
203 863-0003
21 Reade Place
Suite 2100
Poughkeepsie, NY 12601
203 863-0003
© 2024 The Plastic & Reconstructive Surgery Group - All Rights Reserved - Featured Realself Breast Reconstruction Expert - Terms of Use - Sitemap
News
Study Once More Underpins The Clinical Value Of FDA-Cleared Breast Cancer Recurrence Assay
Posted Date: December 22, 2010
Agendia, a world leader in molecular cancer diagnostics, announced recently that together with several groups of scientific collaborators it has identified a major role for TSPYL5 in the genesis of breast cancer.
Agendia, a world leader in molecular cancer diagnostics, announced recently that together with several groups of scientific collaborators it has identified a major role for TSPYL5, one of its MammaPrint breast cancer prognosis genes, in the genesis of breast cancer. The study entitled: “TSPYL5 suppresses p53 levels and function by physical interaction with USP7”, was published in Nature Cell Biology, one of the foremost scientific journals.
Click here to learn more.